Previous 10 | Next 10 |
In this episode of Rule Breaker Investing , Motley Fool co-founder David Gardner and Motley Fool analysts Karl Thiel and Maria Gallagher review three Five-Stock Samplers. Learn about their businesses, why they went up or down, and what lessons you can take away from this review so that you ca...
Original art by the Author Does The Market Make Any Sense? Does it make any sense that the S&P 500 ( SPY ) is only about 17% percent below an all-time high? Does it make any sense that the NASDAQ 100 ( QQQ ) is only 11% off its all-time high? Does it make any sense that we alwa...
Introduction Since my last article on bluebird bio (BLUE) about 3 months ago, the company has faced several setbacks such as the delay in filing BLA of its lead program, Zynteglo for the treatment of transfusion-dependent β-thalassemia ("TDT"), delay in the first commercial trea...
Shares of bluebird bio (NASDAQ: BLUE) were soaring 9.1% higher as of 3:13 p.m. EDT on Thursday after rising as much as 10.4% earlier in the day. The nice gain came as the overall stock market jumped on news that the Federal Reserve Board announced it would inject another $2.3 trillion into t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Investors know that drug development is an expensive and risky endeavor. Most drug candidates fail clinical trials, which is why the direct research and development necessary for each drug candidate that finally makes it to market costs hundreds of millions of dollars. That makes successful drug...
BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc . (Nasdaq: BLUE) today announced the submission of th...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Calithera Biosciences (NASDAQ: CALA ) initiated with Buy rating and $6 (34% upside) price target at Jefferies. More news on: Calithera Biosciences, Inc., bluebird bio, Inc., Charles River Laboratories International, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Bluebird bio (NASDAQ: BLUE ) provides an update in response to the global COVID-19 pandemic. More news on: bluebird bio, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...